Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma × elotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 50 Recurrence 9 Smoldering Multiple Myeloma 2 Neoplasms, Plasma Cell 2 Primary Myelofibrosis 1 Polycythemia Vera 1 Neoplasms 1 Lymphoma 1 Leukemia, Plasma Cell 1 Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cyclophosphamide 380 Rituximab 328 Etoposide 190 Vincristine 175 Filgrastim 172 Doxorubicin 169 Prednisone 142 Radiotherapy 135 Cytarabine 133 fludarabine phosphate 120 Melphalan 110 Methotrexate 109 Peripheral Blood Stem Cell Transplantation 107 fludarabine 100 Busulfan 85 Dexamethasone 74 Carmustine 63 Granulocyte Colony-Stimulating Factor 60 Tacrolimus 59 Mycophenolic Acid 56 Gemcitabine 56 Whole-Body Irradiation 55 Bendamustine Hydrochloride 55 Antilymphocyte Serum 54 Lenalidomide 52 Cyclosporine 51 Ifosfamide 50 Bortezomib 48 Methylprednisolone 42 Leucovorin 39

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01239797 2022-06-01

ELOQUENT - 2

Bristol-Myers Squibb

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡